Keyphrases
Meta-analysis
100%
Randomized Trial
100%
COVID-19
100%
Hospitalized Adults
100%
Individual Participant Data
100%
Non-hospitalized
100%
Hydroxychloroquine
100%
Randomized Controlled Trial
27%
Hospitalization
27%
Comorbidity
18%
Treatment Group
18%
Symptom Duration
18%
Load Reduction
9%
Hospitalization Rate
9%
Severe Disease
9%
Viral Load
9%
Clinical Benefit
9%
Confidence Interval
9%
Early Treatment
9%
Odds Ratio
9%
No Significant Difference
9%
Pooled Analysis
9%
Polymerase Chain Reaction
9%
Viral Clearance
9%
Generalized Linear Mixed Model
9%
Group Effect
9%
Oral Therapy
9%
Individual Participant Data Meta-analysis
9%
Longitudinal Binary Data
9%
Positive Check
9%
Log-likelihood Ratio Test
9%
Medicine and Dentistry
Meta-Analysis
100%
COVID-19
100%
Hydroxychloroquine
100%
Outpatient
27%
Randomized Controlled Trial
27%
Comorbidity
18%
Treatment Group
18%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Pooled Analysis
9%
Viral Clearance
9%
Mixed Model
9%
Odds Ratio
9%
Polymerase Chain Reaction
9%
Diseases
9%
Oral
9%
Neuroscience
Coronavirus
100%
Meta-Analysis
100%
Coronavirinae
100%
Hydroxychloroquine
100%
Randomized Controlled Trial
27%
Comorbidity
18%
SARS Coronavirus
9%
Polymerase Chain Reaction
9%
Pharmacology, Toxicology and Pharmaceutical Science
Coronavirinae
100%
Hydroxychloroquine
100%
Diseases
100%
Randomized Controlled Trial
27%
Comorbidity
18%
Treatment Group
18%
Mixed Model
9%
SARS Coronavirus
9%
Viral Clearance
9%
Immunology and Microbiology
COVID-19
100%
Hydroxychloroquine
100%
Comorbidity
18%
Viral Load
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Viral Clearance
9%
Polymerase Chain Reaction
9%
Biochemistry, Genetics and Molecular Biology
Coronavirinae
100%
Randomized Controlled Trial
50%
Comorbidity
33%
SARS Coronavirus
16%
Virus Load
16%
Viral Clearance
16%
Polymerase Chain Reaction
16%